Successful Proof of Mechanism

An important step - Proof of Mechanism - has been achieved. That means that we have shown that parts of XtriG bind to a drug and that the drug is released, in three independent tests, as an intact substance in saliva.

NorInvent develops XtriG, the Company’s patented Drug Delivery platform for pharmaceutical uptake via the oral mucosa. XtriG aims at providing pharmaceutical companies with a means to give their existing drugs enhanced properties, such as significantly faster onset, reduced environmental impact and reduced dosage compared to peroral drug administration (swallowing of pills).

As has been previously announced, Proof of Mechanism is an important partial goal in the development of XtriG. This goal has now been reached. We now have data showing that parts of XtriG bind to ibuprofen and that ibuprofen then is released from these in saliva. The release has been shown in three independent tests - and the released substance is intact. The fact that the drug is released unaltered after binding is crucial for the pharmaceutical industry to find XtriG to be an interesting drug delivery platform.

This information is information that NorInvent AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on September 29, 2017.

Paul Hasselgren

CEO

+46 760 49 40 90

paul.hasselgren@norinvent.com

NorInvent AB (publ)

Medicon Village

SE-22381 Lund

SWEDEN

+46 46 25 66 60

info@norinvent.com